The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Feb 11, 2025 • 58min
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Jan 27, 2025 • 1h 21min
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Jan 13, 2025 • 1h 2min
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Jan 2, 2025 • 60min
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, a general partner at GV and a seasoned hematologist, shares insights from his journey in biotech. He discusses the importance of company culture and how his diverse background shaped his investment philosophy. Schenkein emphasizes embracing failure as a vital part of innovation and reveals the interplay between AI and drug discovery. He reflects on his transition from CEO to venture capitalist, underlining the need for diverse strategies in investing. His vision focuses on patient outcomes and the transformative potential of biotech advancements.
Dec 11, 2024 • 1h 2min
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Nov 25, 2024 • 1h
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Nov 6, 2024 • 1h 11min
Ep167: Leslie Williams on transfer RNA therapies
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
Oct 15, 2024 • 1h 4min
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Chris Garcia, a biochemistry professor at Stanford and biotech entrepreneur, dives into the fascinating world of protein engineering for cancer and autoimmune treatments. He shares his transformative journey from aspiring tennis player to leading immunology research. Topics include the ingenious application of AI in protein design, innovative strategies for enhancing clinical trials, and the significance of T-cell interactions in cancer therapies. Personal anecdotes of endurance running cleverly illustrate how these experiences spark creative breakthroughs in science.
Sep 26, 2024 • 1h 3min
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
Sep 5, 2024 • 57min
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
